A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Non-obstructive Hypertrophic Cardiomyopathy

In brief

FORTITUDE-HCM is a global, multicenter, double-blind, parallel-group, placebo-controlled Phase 2b study that will assess the efficacy and safety of ninerafaxstat compared to placebo on top of Standard of Care in patients with symptomatic nHCM

Key facts

Study ID

NCT07023614

Run by

Imbria Pharmaceuticals, Inc.

People needed

165

Starts

2025-10-06

Expected to finish

2026-12-01

Last updated by the study team

2026-05-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Imbria Investigational Site — Los Angeles, California, United States (enrolling)
• Imbria Investigational Site — La Jolla, California, United States (enrolling)
• Imbria Investigational Site — Washington D.C., District of Columbia, United States (enrolling)
• Imbria Investigational Site — Miami, Florida, United States (enrolling)
• Imbria Investigational Site — Chicago, Illinois, United States (enrolling)
• Imbria Investigational Site — San Francisco, California, United States (enrolling)
• Imbria Investigational Site — Baltimore, Maryland, United States (enrolling)
• Imbria Investigational Site — Boston, Massachusetts, United States (enrolling)
• Imbria Investigational Site — Burlington, Massachusetts, United States (enrolling)
• Imbria Investigational Site — Grand Rapids, Michigan, United States (enrolling)
• Imbria Investigational Site — Rochester, Minnesota, United States (enrolling)
• Imbria Investigational Site — St Louis, Missouri, United States (enrolling)
• Imbria Investigational Site — New York, New York, United States (enrolling)
• Imbria Investigational Site — Charlotte, North Carolina, United States (enrolling)
• Imbria Investigational Site — Portland, Oregon, United States (enrolling)
• Imbria Investigational Site — Philadelphia, Pennsylvania, United States (enrolling)
• Imbria Investigational Site — Philadelphia, Pennsylvania, United States (enrolling)
• Imbria Investigational Site — Houston, Texas, United States (enrolling)
• Imbria Investigational Site — Plano, Texas, United States (enrolling)
• Imbria Investigational Site — Charlottesville, Virginia, United States (enrolling)
• Imbria Investigational Site — Richmond, Virginia, United States (enrolling)
• Imbria Investigational Site — Graz, Austria (enrolling)
• Imbria Investigational Site — Edegem, Belgium (enrolling)
• Imbria Investigational Site — Montpellier, France (enrolling)
• Imbria Investigational Site — Paris, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.